Compare TXT & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXT | PRME |
|---|---|---|
| Founded | 1923 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 536.4M |
| IPO Year | 1994 | 2022 |
| Metric | TXT | PRME |
|---|---|---|
| Price | $87.13 | $3.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $95.18 | $7.56 |
| AVG Volume (30 Days) | 1.7M | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | 18.01 | ★ 18.18 |
| EPS | ★ 2.67 | N/A |
| Revenue | ★ $14,799,000,000.00 | $4,632,000.00 |
| Revenue This Year | $5.87 | $7.06 |
| Revenue Next Year | $4.54 | $47.01 |
| P/E Ratio | $32.83 | ★ N/A |
| Revenue Growth | 8.01 | ★ 55.28 |
| 52 Week Low | $78.12 | $2.67 |
| 52 Week High | $101.57 | $6.94 |
| Indicator | TXT | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 45.78 |
| Support Level | $86.38 | $2.73 |
| Resistance Level | $91.17 | $3.32 |
| Average True Range (ATR) | 2.13 | 0.18 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 51.12 | 54.62 |
Textron is a conglomerate that designs, manufactures, and services a range of specialty aircraft including small jets, propeller-driven airplanes, helicopters, and tilt-rotor aircraft. Textron Aviation manufactures and services Cessna and Beechcraft planes. Bell is a helicopter and tilt-rotor manufacturer and servicer for both commercial and military customers. Textron Systems produces uncrewed aircraft and armored vehicles for the military market as well as aircraft simulators and training for the commercial and military markets. Textron Industrial houses the Kautex business, which manufactures plastic fuel tanks for conventional and hybrid motor vehicles, and other subsidiaries that produce specialized vehicles such as golf carts and all-terrain vehicles.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.